Zydus Sentynl Licenses Alvelestat for Rare Lung Disease
By ThePip Desk
Sentynl Therapeutics, part of Zydus Lifesciences, secures rights to alvelestat, a potential first-in-class oral treatment for Alpha-1 Antitrypsin Deficiency Lung Disease (AATD-LD) in the U.S.
Zydus Lifesciences’ wholly-owned subsidiary, Sentynl Therapeutics, Inc., has finalized an option and license agreement with Mereo BioPharma Group plc. This strategic partnership grants Sentynl the exclusive rights to commercialize alvelestat in the United States, alongside global manufacturing rights for the drug.
Alvelestat, a neutrophil elastase inhibitor, is being developed as a potential first-in-class oral treatment for Alpha-1 Antitrypsin Deficiency Associated Lung Disease (AATD-LD). This rare, progressive genetic lung condition affects a significant population in the U.S.
Addressing a Rare Disease Market
- AATD-LD impacts an estimated 50,000-80,000 individuals across the United States.
- Alvelestat is currently being readied for Phase 3 clinical trials, which could commence in early 2027.
- If approved, it would mark a significant advancement as the first oral treatment option for this patient group.
Under the terms of the agreement, Mereo BioPharma retains commercial rights for alvelestat in all territories outside the United States. Sentynl’s involvement extends to providing crucial funding for the alvelestat Phase 3 development program upon the exercise of its option.
Financial Structure of the Deal
The financial framework of this agreement outlines several key payment milestones for Mereo. These payments are tied to the progression and commercialization efforts of alvelestat.
- Mereo will receive a non-refundable option fee from Sentynl.
- Upon the exercise of the option, Mereo is eligible for up to $40 million in upfront and R&D payments.
- These payments are slated to continue until the New Drug Application (NDA) filing.
- Furthermore, Mereo stands to receive double-digit tiered royalties based on the U.S. net sales of alvelestat.
This collaboration underscores Zydus Lifesciences’ strategic focus through its subsidiary, Sentynl, on addressing rare disease markets with high unmet needs. The move positions Sentynl as a key player in the development and future commercialization of AATD-LD treatments, pending successful clinical outcomes and regulatory approvals.